Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2006-06-16
2010-11-09
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085100, C424S198100, C514S002600, C530S351000
Reexamination Certificate
active
07829077
ABSTRACT:
The invention relates to the use of at least one cytokine from the IL-6 family -gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.
REFERENCES:
patent: 5928636 (1999-07-01), Alber et al.
patent: 6177074 (2001-01-01), Glue et al.
patent: 6284237 (2001-09-01), Clark et al.
patent: 6348191 (2002-02-01), Clark et al.
patent: 6461605 (2002-10-01), Cutler et al.
patent: 6509154 (2003-01-01), de Paillette
patent: 6524570 (2003-02-01), Glue et al.
patent: 6685931 (2004-02-01), Grint et al.
patent: 1 001 801 (2000-05-01), None
patent: 0 858 343 (2004-03-01), None
patent: 2 006 776 (1989-05-01), None
patent: 2 224 246 (2005-03-01), None
patent: 00/37096 (2000-06-01), None
Patterson, B.K., et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J. Clin. Invest. 2001, vol. 107, p. 287-294.
Chevaliez S et al. Interferons and their use in persistent viral infections. Handbook of Experimental Pharmacology. 2009, vol. 189, p. 203-241.
International Search Report issued Jan. 4, 2007 in the International (PCT) Application of which the present application is the U.S. National Stage.
Hoofnagle et al., “Randomized, Controlled Trial of Recombinant Human α-Interferon in Patients with Chronic Hepatitis B,” Gastroenterology, Nov. 1988, vol. 95, pp. 1318-1325.
Manns et al., “Peginterferon alfa-2b Plus Ribavirin Compared with Interferon alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomised Trial,” The Lancet, Sep. 22, 2001, vol. 358, pp. 958-965.
Gale et al., “Evidence That Hepatitis C Virus Resistance to Interferon is Mediated Through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein,” Virology (1997), vol. 230, (Article No. VY978493) pp. 217-227.
Taylor et al., “Inhibition of the Interferon-Inducible Protein Kinase PKR by HCV E2 Protein,” Science (1999) vol. 285, pp. 107-110.
Blindenbacher et al., “Expression of Hepatitis C Virus Proteins Inhibits Interferon α Signaling in the Liver of Transgenic Mice,” Gastroenterology (2003), vol. 124, pp. 1465-1475.
Duong et al., “Hepatitis C Virus Inhibits Interferon Signaling Through Up-Regulation of Protein Phosphatase 2A,” Gastroenterology (2004), vol. 126, pp. 263-277.
Heinrich et al., “Interleukin-6-Type Cytokine Signalling Through the gp130/Jak/STAT Pathway,” Biochem J. (1998), vol. 334, pp. 297-314.
Zhu et al., “STAT3 Induces Anti-Hepatitis C Viral Activity in Liver Cells,” Biochemical and Biophysical Research Communications (2004), vol. 324, pp. 518-528.
Pietschmann et al., “Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture,” Journal of Virology (Apr. 2002), vol. 76, No. 8, pp. 4008-4021.
Chomczynski et al., “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,” Analytical Biochemistry (1987), vol. 162, pp. 156-159.
International Search Report issued Jan. 4,2007 in the International (PCT) Application of which the present application is the U.S. National Stage.
Aldabe Arregui Rafael
Civeira Murillo María Pilar
Larrea Leoz Esther
Prieto Valtueña Jesús
Hissong Bruce D
Landsman Robert
Proyecto De Biomedicina Cima, S.L.
Wenderoth Lind & Ponack LLP
LandOfFree
Treatment of hepatitis C with compositions comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatitis C with compositions comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatitis C with compositions comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199505